Amylyx Pharmaceuticals, Inc. today announced the closing of an oversubscribed $135 million Series C financing, led by Viking Global Investors, to support the clinical development and potential launch plans for lead product candidate AMX0035, for the potential treatment of ALS, and further research and development in other neurodegenerative diseases.

Amylyx Pharmaceuticals, Inc. is a global company committed to the mission of discovery and development of treatments for relentless and progressing neurodegenerative diseases. We work collaboratively across everything we do, aspiring to help support and create #MoreMoments for the neurodegenerative disease community. 

https://www.amylyx.com/

Pharmaceutical

Cambridge

Amylyx Pharmaceuticals

Amylyx Pharmaceuticals Closes $135M Series C Financing Led By Viking Global Investors To Support Late Stage Development Of Lead Product Candidate Amx0035 For The Treatment Of Als

Amylyx Pharmaceuticals Closes $135M Series C Financing Led By Viking Global Investors To Support Late Stage Development Of Lead Product Candidate Amx0035 For The Treatment Of Als

Description

Company Information

Related People

Funding Insights

Amylyx Pharmaceuticals Closes $135M Series C Financing Led By Viking Global Investors To Support Late Stage Development Of Lead Product Candidate Amx0035 For The Treatment Of Als

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information